▲ bullish
Impact
PhasePhase 3
Time to marketPhase 3 trials are enrolling now; topline data expected in 2027. If successful, a 505(b)(2) NDA submission would follow, with potential FDA approval possibly in 2028-2029.
Bimatoprost Drug Pad-IOL System bimatoprost Updated Oct 24
What to watch
Watch for Phase 3 topline readout (expected in 2027, no precise date yet) as the defining binary catalyst. The FIH 4-year data (Oct 2026) de-risks Phase 3 replication risk somewhat, but Phase 3 results will determine whether the 505(b)(2) NDA submission proceeds. Also monitor FDA alignment updates and any accelerated enrollment announcements.
Bull case
- 4-year FIH data (Oct 2026) showed 86% of patients off all topical glaucoma drops with no product-related adverse events, strong durability and safety signal.
- Massive institutional accumulation in Q2 2026: BlackRock doubled (+392%), Vanguard doubled (+1,960%), Barclays doubled (+1,478%), and multiple others added or doubled positions.
- Analyst consensus is strong-buy (5 strong buy, 4 buy, 1 hold) with a mean price target of $44 vs ~$28.50 current, implying ~54% upside.
Bear case
- Phase 3 may fail to replicate Phase 1/2 results, the 4-year FIH data (N=21 evaluable) is a small sample and may not generalize to the broader Phase 3 population.
- Cash burn is accelerating (net loss $39.9M in 2025 vs $29.2M in 2024), and while $251M runway runs through 2028, any Phase 3 delays would increase dilution risk.
- Competition from existing glaucoma MIGS devices (iStent, Hydrus) and AbbVie's Durysta bimatoprost implant could limit commercial adoption even if approved.